Patent ID: 9107918
Filing Date: 2015-08-18
Classification: A61K,A61P,C12Q,G01N,Y02A

Abstract:
1. A method for treating cancer in a human subject, comprising: (i) measuring a pre-treatment mRNA expression level of the AMD1 gene, CTSC gene, EIF1AX gene, C12orf30 gene, DDX54 gene, PTPN2 gene, and TBX3 gene in a biosample derived from a subject having colorectal cancer; (ii) calculating, using the measured pre-treatment mRNA expression level, a pre-treatment value of the best tumor response rate using formula (1) wherein: wherein A represents an expression level of the AMD1 gene, B represents an expression level of the CTSC gene, C represents an expression level of the EIF1AX gene, D represents an expression level of the C12orf30 gene, E represents an expression level of the DDX54 gene, F represents an expression level of the PTPN2 gene, and G represents an expression level of the TBX3 gene; (iii) administering to the subject at least one of irinotecan, SN-38, a salt of irinotecan, and a salt of SN-38; (iv) measuring a post-treatment mRNA expression level of the AMD1 gene, CTSC gene, EIF1AX gene, C12orf30 gene, DDX54 gene, PTPN2 gene, and TBX3 gene in a biosample derived from the subject; (v) calculating, using the measured post-treatment mRNA expression level, a post-treatment value of the best tumor response rate using formula (1); (vi) comparing the pre-treatment value calculated in (ii) with the post-treatment value calculated in (v); and (vii) continuing the administering of said at least one of irinotecan, SN-38, a salt of irinotecan, and a salt of SN-38 when the value post-treatment value calculated in (v) is equal to or higher than the pre-treatment value calculated in (ii); or halting the administering of said at least one of irinotecan, SN-38, a salt of irinotecan, and a salt of SN-38 when the post-treatment value calculated in (v) is lower than the pre-treatment value calculated in (ii).